Collegium Pharmaceutical (COLL) EBIT: 2016-2025
Historic EBIT for Collegium Pharmaceutical (COLL) over the last 10 years, with Sep 2025 value amounting to $62.1 million.
- Collegium Pharmaceutical's EBIT rose 78.21% to $62.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $157.0 million, marking a year-over-year decrease of 18.86%. This contributed to the annual value of $169.9 million for FY2024, which is 1.76% up from last year.
- Latest data reveals that Collegium Pharmaceutical reported EBIT of $62.1 million as of Q3 2025, which was up 76.86% from $35.1 million recorded in Q2 2025.
- In the past 5 years, Collegium Pharmaceutical's EBIT registered a high of $62.1 million during Q3 2025, and its lowest value of -$34.1 million during Q4 2021.
- Over the past 3 years, Collegium Pharmaceutical's median EBIT value was $38.1 million (recorded in 2024), while the average stood at $41.4 million.
- Per our database at Business Quant, Collegium Pharmaceutical's EBIT plummeted by 327.54% in 2021 and then soared by 424.69% in 2023.
- Over the past 5 years, Collegium Pharmaceutical's EBIT (Quarterly) stood at -$34.1 million in 2021, then soared by 134.46% to $11.8 million in 2022, then surged by 424.69% to $61.7 million in 2023, then slumped by 38.22% to $38.1 million in 2024, then surged by 78.21% to $62.1 million in 2025.
- Its last three reported values are $62.1 million in Q3 2025, $35.1 million for Q2 2025, and $21.7 million during Q1 2025.